Italy temporarily halts use of AstraZeneca's Covid-19 vaccine

AstraZeneca insists its vaccine offers strong protection against Covid-19

AstraZeneca pharmaceutical company argued that its vaccine, which caused controversy due to its side effects, provided 76 percent protection against the new type of coronavirus (Covid-19).

In the statement made by AstraZeneca, it was stated that new studies were carried out on the Covid-19 vaccine developed with Oxford University.

In the statement, it was noted that the vaccine provided strong protection with new studies and the vaccine was 76 percent effective in preventing Covid-19.

AstraZeneca shared data on interim safety and efficacy analyzes of the 3rd phase studies of the Covid-19 vaccine on March 22, on 32 thousand 449 people in the USA.

The US Data and Security Monitoring Board announced on March 23 that there is concern that AstraZeneca may have provided an incomplete view of useful data.

In the US, the Food and Drug Administration and the Centers for Disease Control and Prevention must approve the vaccine after extensive evaluation of data provided by independent advisory committees to allow the use of the AstraZeneca vaccine.


The administration of Oxford-AstraZeneca, one of the first vaccines developed against Covid-19, was temporarily suspended in some countries on suspicion that it could cause blood clotting, causing vascular occlusion and pulmonary embolism.

The World Health Organization stated that the benefits of the vaccine are more than the risks, “Its use should continue to save lives.” He had made the explanation.

The European Union Medicines Agency and the UK Medicines and Health Products Regulatory Agency also recommended the use of the vaccine.


Leave a Reply

Your email address will not be published. Required fields are marked *